Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
First In Human Study of CX-801 in Advanced Solid Tumors
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- CytomX Therapeutics
- Target Recruit Count
- 121
- Registration Number
- NCT06462794
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
First In Human Study of CX-2051 in Advanced Solid Tumors
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- CytomX Therapeutics
- Target Recruit Count
- 124
- Registration Number
- NCT06265688
- Locations
- 🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Carolina BioOncology Institute, PLLC, Huntersville, North Carolina, United States
A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- CytomX Therapeutics
- Target Recruit Count
- 83
- Registration Number
- NCT05387265
- Locations
- 🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸Sarah Cannon Research Institute, LLC, Nashville, Tennessee, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
- Conditions
- NeoplasmsBreast NeoplasmsBreast CancerBreast Neoplasms, Triple-NegativeBreast Neoplasms, Hormone Receptor Positive/HER2 Negative
- Interventions
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- CytomX Therapeutics
- Target Recruit Count
- 125
- Registration Number
- NCT04596150
- Locations
- 🇺🇸
Moores Cancer Center, La Jolla, California, United States
🇺🇸Los Angeles Hematology Oncology Medical, Los Angeles, California, United States
🇺🇸USC Norris Cancer Center, Los Angeles, California, United States
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
- Conditions
- Unresectable or Metastatic MelanomaSolid Tumor
- Interventions
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2021-12-01
- Lead Sponsor
- CytomX Therapeutics
- Target Recruit Count
- 3
- Registration Number
- NCT03993379
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸Beacon Cancer Care, Coeur d'Alene, Idaho, United States
- Prev
- 1
- 2
- Next
News
CytomX Doses First Patient in Combination Trial of CX-801 with Keytruda for Metastatic Melanoma
CytomX Therapeutics has dosed the first patient in a Phase 1 trial combining its masked interferon alpha-2b (CX-801) with Merck's Keytruda in patients with metastatic melanoma.
CytomX's CX-2051 Shows Promising 28% Response Rate in Advanced Colorectal Cancer Phase 1 Trial
CytomX's EpCAM-targeting antibody-drug conjugate CX-2051 demonstrated a 28% confirmed response rate in late-line colorectal cancer patients, significantly outperforming current standard therapies with single-digit response rates.
Biopharma Industry Faces Continued Layoffs in 2025 Amid Strategic Realignments
Biopharma companies continue to announce layoffs in 2025, driven by strategic realignments, pipeline reprioritizations, and challenging financial conditions.
CytomX Therapeutics Initiates Combination Therapy Arm in Phase 1 Melanoma Trial
CytomX Therapeutics has dosed the first patient in a combination arm studying CX-801 with Keytruda (pembrolizumab) for patients with metastatic melanoma.